[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CR20150242A - Terapia adyuvante con inhibidores de quinasa de la familia tec - Google Patents

Terapia adyuvante con inhibidores de quinasa de la familia tec

Info

Publication number
CR20150242A
CR20150242A CR20150242A CR20150242A CR20150242A CR 20150242 A CR20150242 A CR 20150242A CR 20150242 A CR20150242 A CR 20150242A CR 20150242 A CR20150242 A CR 20150242A CR 20150242 A CR20150242 A CR 20150242A
Authority
CR
Costa Rica
Prior art keywords
adjutive
therapy
tec family
quinasa
inhibitors
Prior art date
Application number
CR20150242A
Other languages
English (en)
Inventor
Joseph J Buggy
Tarak Mody
Richard B Love
John C Byrd
Betty Chang
Jason A Dubovsky
Natarajan Muthusamy
Amy Jo Johnson
Original Assignee
Pharmacyclics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50628113&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20150242(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacyclics Inc filed Critical Pharmacyclics Inc
Publication of CR20150242A publication Critical patent/CR20150242A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)

Abstract

En la presente descripción se describen métodos y composiciones que comprenden un inhibidor de quinasa de la familia TEC covalente para usar en la terapia adyuvante que incluye la terapia adyuvante para el cáncer, la 5 vacunación y el tratamiento de trastornos inmunes e infecciones patógenas.
CR20150242A 2012-11-02 2015-05-08 Terapia adyuvante con inhibidores de quinasa de la familia tec CR20150242A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261722107P 2012-11-02 2012-11-02
US201361785868P 2013-03-14 2013-03-14
PCT/US2013/068132 WO2014071231A1 (en) 2012-11-02 2013-11-01 Tec family kinase inhibitor adjuvant therapy

Publications (1)

Publication Number Publication Date
CR20150242A true CR20150242A (es) 2015-08-17

Family

ID=50628113

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20150242A CR20150242A (es) 2012-11-02 2015-05-08 Terapia adyuvante con inhibidores de quinasa de la familia tec

Country Status (22)

Country Link
US (4) US9717731B2 (es)
EP (1) EP2914263A4 (es)
JP (3) JP2015536950A (es)
KR (1) KR20150080592A (es)
CN (2) CN104994858A (es)
AU (3) AU2013337663A1 (es)
BR (1) BR112015010059A2 (es)
CA (1) CA2890111A1 (es)
CL (1) CL2015001147A1 (es)
CR (1) CR20150242A (es)
DO (1) DOP2015000098A (es)
EA (1) EA201590822A1 (es)
HK (1) HK1214508A1 (es)
IL (1) IL238548A0 (es)
MX (2) MX2015005633A (es)
NI (1) NI201500062A (es)
PE (1) PE20151604A1 (es)
PH (1) PH12015500985A1 (es)
SG (1) SG11201503459SA (es)
TN (1) TN2015000170A1 (es)
TW (1) TW201427664A (es)
WO (1) WO2014071231A1 (es)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
RU2734822C2 (ru) 2008-06-27 2020-10-23 Селджен Кар Ллс Гетероарильные соединения и их применение
KR101705158B1 (ko) 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Egfr 억제제 및 질환 치료방법
NZ753024A (en) 2010-06-03 2020-08-28 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
CN103096716B (zh) 2010-08-10 2016-03-02 西建阿维拉米斯研究公司 Btk抑制剂的苯磺酸盐
JP5909239B2 (ja) 2010-10-26 2016-04-26 マーズ インコーポレイテッド アルギナーゼ阻害剤としてのボロネート
ES2635713T3 (es) 2010-11-01 2017-10-04 Celgene Car Llc Compuestos de heteroarilo y usos de los mismos
US8975249B2 (en) 2010-11-01 2015-03-10 Celgene Avilomics Research, Inc. Heterocyclic compounds and uses thereof
US8796255B2 (en) 2010-11-10 2014-08-05 Celgene Avilomics Research, Inc Mutant-selective EGFR inhibitors and uses thereof
WO2013063401A1 (en) 2011-10-28 2013-05-02 Celgene Avilomics Research, Inc. Methods of treating a bruton's tyrosine kinase disease or disorder
ES2698298T3 (es) 2012-03-15 2019-02-04 Celgene Car Llc Sales de un inhibidor de quinasa receptor de factor de crecimiento epidérmico
US9056839B2 (en) 2012-03-15 2015-06-16 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor
CA2879570A1 (en) 2012-07-24 2014-01-30 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
AU2013337663A1 (en) 2012-11-02 2015-06-11 Pharmacyclics Llc TEC family kinase inhibitor adjuvant therapy
WO2014100748A1 (en) 2012-12-21 2014-06-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
KR20150119012A (ko) 2013-02-08 2015-10-23 셀진 아빌로믹스 리서치, 인코포레이티드 Erk 억제제 및 이의 용도
US9974774B2 (en) 2013-07-26 2018-05-22 Race Oncology Ltd. Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
CA2919996A1 (en) * 2013-08-02 2015-02-05 Pharmacyclics Llc Methods for the treatment of solid tumors
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
EA201690746A1 (ru) * 2013-10-25 2016-12-30 Фармасайкликс Элэлси Лечение с применением ингибиторов тирозинкиназы брутона и иммунотерапии
US10314842B2 (en) * 2013-12-02 2019-06-11 Cornell University Methods for treating B cell proliferative disorders
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
WO2015143400A1 (en) 2014-03-20 2015-09-24 Pharmacyclics, Inc. Phospholipase c gamma 2 and resistance associated mutations
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
WO2015187848A1 (en) * 2014-06-04 2015-12-10 Sampath Deepa Hdac inhibitor and btk inhibitor combinations
US20150361504A1 (en) * 2014-06-13 2015-12-17 Pharmacyclics Llc Biomarker for predicting response of cll to treatment with a btk inhibitor
WO2016010961A1 (en) * 2014-07-15 2016-01-21 Abbvie Inc. Enzyme occupancy assay
WO2016015044A1 (en) * 2014-07-25 2016-01-28 Northeastern University Biopolymer-nanoparticle composite implant for tumor cell tracking
DK3179858T3 (da) 2014-08-13 2019-07-22 Celgene Car Llc Forme og sammensætninger af en ERK-inhibitor
WO2016044774A1 (en) * 2014-09-18 2016-03-24 Pharmacyclics Llc Dendritic cell based vaccine with bruton's tyrosine kinase inhibitor
WO2016090107A2 (en) * 2014-12-04 2016-06-09 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
WO2016123073A1 (en) 2015-01-26 2016-08-04 Children's Medical Center Corporation Treatment of infectious diseases
IL303543A (en) 2015-02-18 2023-08-01 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
WO2016138542A1 (en) * 2015-02-28 2016-09-01 Cyprus Therapeutics, Inc. Methods for inhibiting tumors and drug resistance
WO2016167236A1 (ja) 2015-04-13 2016-10-20 第一三共株式会社 Mdm2阻害剤とbtk阻害剤との併用治療法
WO2016172342A1 (en) 2015-04-21 2016-10-27 Eiger Biopharmaceuticals, Inc. Pharmaceutical compositions comprising lonafarnib and ritonavir
CN107708811B (zh) 2015-04-21 2021-04-30 恩立夫克治疗有限责任公司 治疗性汇集的血液凋亡细胞制剂与其用途
US11554138B2 (en) 2015-07-16 2023-01-17 The University Of Hong Kong Bismuth(III) complexes as adjuvants in the treatment of cancer using platinum-based chemotherapy
CN108024996A (zh) * 2015-07-31 2018-05-11 药品循环有限责任公司 布鲁顿氏酪氨酸激酶抑制剂组合和其用途
CA2994850A1 (en) 2015-08-12 2017-02-16 Portola Pharmaceuticals, Inc. Cerdulatinib for treating myeloma
MD3368541T2 (ro) * 2015-10-30 2020-09-30 Calithera Biosciences Inc Compoziții și procedee de inhibare a activității arginazei
CN108367006B (zh) 2015-12-04 2021-12-31 博尔托拉制药公司 用于治疗血液癌症的赛度替尼
EP3416661A4 (en) 2016-02-18 2020-03-04 Enlivex Therapeutics Ltd. COMBINATION OF IMMUNOTHERAPY AND CYTOKINE CONTROL THERAPY FOR THE TREATMENT OF CANCER
PT3416675T (pt) 2016-02-19 2021-06-14 Eiger Biopharmaceuticals Inc Tratamento de infeção pelo vírus da hepatite delta com interferão lambda
EP3318276A1 (en) 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
CN106405086A (zh) * 2016-09-21 2017-02-15 四川大学华西医院 一种肺癌筛查试剂盒
CN110139669A (zh) 2016-11-03 2019-08-16 朱诺治疗学股份有限公司 T细胞疗法和btk抑制剂的组合疗法
EP3548046A2 (en) 2016-12-03 2019-10-09 Juno Therapeutics, Inc. Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors
JP7018949B2 (ja) 2016-12-22 2022-02-14 カリセラ バイオサイエンシズ,インコーポレイテッド アルギナーゼ活性を阻害するための組成物及び方法
CN108732280B (zh) * 2017-04-18 2022-07-08 广东东阳光药业有限公司 一种分离检测盐酸达卡他韦及其光学异构体的方法
WO2019014684A1 (en) * 2017-07-14 2019-01-17 Ohio State Innovation Foundation EXPANSION OF IMMUNE CELLS WITH INTERLEUKIN-INDUCIBLE T CELL KINASE-INHIBITING COMPOUNDS
US11897917B2 (en) 2017-09-27 2024-02-13 The University Of York Bioconjugation of polypeptides
CZ2017787A3 (cs) 2017-12-08 2019-06-19 Zentiva, K.S. Farmaceutické kompozice obsahující ibrutinib
CN112584902A (zh) 2018-05-03 2021-03-30 朱诺治疗学股份有限公司 嵌合抗原受体(car)t细胞疗法和激酶抑制剂的组合疗法
WO2019213606A2 (en) 2018-05-04 2019-11-07 Portola Pharmaceuticals, Inc. Solid forms of cerdulatinib
CN111110685A (zh) * 2018-10-31 2020-05-08 正大天晴药业集团股份有限公司 一种含伊布替尼的药物组合物及其应用
US20220339156A1 (en) * 2019-09-09 2022-10-27 The Children's Hospital Of Philadelphia Compositions and methods for treatment of disorders associated with clec16a dysfunction or loss
CA3154257A1 (en) 2019-10-14 2021-04-22 Principia Biopharma Inc. Methods for treating immune thrombocytopenia by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
WO2021093790A1 (en) * 2019-11-11 2021-05-20 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric genes
US20230158030A1 (en) * 2020-04-10 2023-05-25 Ohio State Innovation Foundation Methods and composition for treatment of covid-19 illness requiring hospitalization
US20230286934A1 (en) * 2020-06-08 2023-09-14 Icahn School Of Medicine At Mount Sinai Use of Multi-Kinase Inhibitors to Treat RNA Virus Infections
KR20240169633A (ko) * 2022-04-05 2024-12-03 코버스 파마슈티칼스, 인크. Th1 세포 활성을 증가시키기 위한 itk 저해제
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2024206869A2 (en) * 2023-03-30 2024-10-03 Board Of Regents, The University Of Texas System Combination of hpk1 inhibitor and axl inhibitor in cancer therapy

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
JP3416147B2 (ja) 1996-01-23 2003-06-16 アイ・シー・エヌ・フアーマシユーテイカルズ・インコーポレイテツド 活性化tリンパ球におけるリバビリン及びリバビリン類似体によるth1型/th2型サイトカインの発現の調節
EP1132393B1 (en) 1996-10-16 2003-04-09 ICN Pharmaceuticals, Inc. L-Ribavirin and uses thereof
US7390619B1 (en) 1998-02-11 2008-06-24 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
US7087236B1 (en) 1998-09-01 2006-08-08 Merrion Research I Limited Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof
AU1096400A (en) 1998-09-28 2000-04-17 Boston Medical Center Corporation Determining resistance to treatment for hepatitis c virus
US6824768B2 (en) 1998-12-18 2004-11-30 Schering Corporation Ribavirin-pegylated interferon alfa induction HCV combination therapy
CN1355708A (zh) 1999-04-19 2002-06-26 先灵公司 包含利巴韦林与抗氧化剂的hcv联合治疗
EP1227844A2 (en) 1999-10-29 2002-08-07 Pharmacyclics, Inc. Compositions for treating atheroma and neoplastic tissue
HUP0300354A3 (en) 2000-03-09 2005-07-28 Schering Corp Hiv immune adjuvant therapy
CA2409154A1 (en) 2000-05-18 2001-11-22 Genetics Institute, Llc Compositions, kits, and methods for identification and modulation of t helper-1 and t helper-2 cells and diseases associated therewith
BR0114636A (pt) 2000-10-18 2004-02-10 Schering Corp Terapia combinada para hcv de interferon-alfa peguilado/ribavirina
US20030103938A1 (en) 2001-05-09 2003-06-05 Alk-Abello A/S Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio
GB0116249D0 (en) 2001-07-05 2001-08-29 Imp College Innovations Ltd Methods
CA2491320A1 (en) 2002-07-15 2004-01-22 Wyeth Methods and compositions for modulating t helper (th) cell development and function
EP2572714A1 (en) 2002-12-30 2013-03-27 3M Innovative Properties Company Immunostimulatory Combinations
WO2004110245A2 (en) 2003-05-16 2004-12-23 Intermune, Inc. Combination therapy for cancer treatment
CA2539702A1 (en) 2003-09-30 2005-04-07 Telethon Institute For Child Health Research Immunotherapy method
NZ568212A (en) 2005-11-04 2012-03-30 Novartis Vaccines & Diagnostic Changing Th1/Th2 balance in split influenza vaccines with adjuvants
WO2007059329A2 (en) 2005-11-16 2007-05-24 Pharmacyclics, Inc. Methods and compositions for treating cancer
GB0605521D0 (en) 2006-03-18 2006-04-26 Isis Innovation Adjuvant
KR20090057035A (ko) 2006-08-21 2009-06-03 유나이티드 세러퓨틱스 코오포레이션 바이러스 감염의 치료를 위한 병용 요법
ES2673973T3 (es) 2006-09-22 2018-06-26 Pharmacyclics Llc Inhibidores de tirosina cinasa de Bruton
US20120065201A1 (en) 2007-03-28 2012-03-15 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
DK2220116T3 (da) 2007-11-12 2012-11-26 Theraclone Sciences Inc Sammensætninger og fremgangsmåder til terapien og diagnosticeringen af influenza
GB0805356D0 (en) 2008-03-25 2008-04-30 Isis Innovation Vaccine adjuvant composition
CN105363034A (zh) 2008-05-23 2016-03-02 香港大学 治疗流感的联合疗法
EP2318031A4 (en) 2008-06-03 2012-09-12 Aethlon Medical Inc IMPROVED METHODS AND DEVICES FOR ANTIVIRAL THERAPY
US8759010B2 (en) 2008-09-26 2014-06-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Host cell kinases as targets for antiviral therapies against HCV infection
JP2012512636A (ja) 2008-12-18 2012-06-07 エフ.ホフマン−ラ ロシュ アーゲー Hcv処置応答についてのバイオマーカー
WO2010093843A2 (en) 2009-02-12 2010-08-19 Vertex Pharmaceuticals Incorporated Hcv combination therapies
MX2011010955A (es) 2009-04-20 2012-04-02 Genentech Inc Terapia complementaria contra el cancer.
US8299070B2 (en) 2009-11-25 2012-10-30 Japan Tobacco Inc. Indole compounds and pharmaceutical use thereof
NZ753024A (en) * 2010-06-03 2020-08-28 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
GB2481611A (en) 2010-06-30 2012-01-04 Statoil Asa Test cell for well fluid assessment
WO2012068531A2 (en) * 2010-11-18 2012-05-24 The General Hospital Corporation Novel compositions and uses of anti-hypertension agents for cancer therapy
CA2839451A1 (en) 2011-06-27 2013-01-03 The Jackson Laboratory Methods and compositions for treatment of cancer and autoimmune disease
WO2013036994A1 (en) 2011-09-16 2013-03-21 Biota Scientific Management Pty Ltd Compounds for the treatment of hcv
US9192664B2 (en) 2011-12-05 2015-11-24 Immunomedics, Inc. Therapeutic use of anti-CD22 antibodies for inducing trogocytosis
US9540382B2 (en) * 2012-06-04 2017-01-10 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
AU2013337663A1 (en) 2012-11-02 2015-06-11 Pharmacyclics Llc TEC family kinase inhibitor adjuvant therapy

Also Published As

Publication number Publication date
HK1214508A1 (zh) 2016-07-29
MX2021003018A (es) 2021-05-27
CA2890111A1 (en) 2014-05-08
US20140371241A1 (en) 2014-12-18
AU2018233032B2 (en) 2020-05-21
AU2020220205A1 (en) 2020-09-10
JP2020183413A (ja) 2020-11-12
TN2015000170A1 (en) 2016-10-03
JP2019031506A (ja) 2019-02-28
NI201500062A (es) 2016-02-16
CN111329989A (zh) 2020-06-26
US9717731B2 (en) 2017-08-01
JP2015536950A (ja) 2015-12-24
US20180071293A1 (en) 2018-03-15
SG11201503459SA (en) 2015-06-29
EA201590822A1 (ru) 2016-01-29
EP2914263A4 (en) 2016-04-27
CN104994858A (zh) 2015-10-21
DOP2015000098A (es) 2015-06-30
EP2914263A1 (en) 2015-09-09
PE20151604A1 (es) 2015-11-04
PH12015500985A1 (en) 2015-08-03
AU2018233032A1 (en) 2018-10-11
AU2013337663A1 (en) 2015-06-11
MX2015005633A (es) 2016-02-03
CL2015001147A1 (es) 2015-06-26
KR20150080592A (ko) 2015-07-09
WO2014071231A1 (en) 2014-05-08
US20200147084A1 (en) 2020-05-14
TW201427664A (zh) 2014-07-16
BR112015010059A2 (pt) 2017-07-11
IL238548A0 (en) 2015-06-30
US20140134265A1 (en) 2014-05-15

Similar Documents

Publication Publication Date Title
CR20150242A (es) Terapia adyuvante con inhibidores de quinasa de la familia tec
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
NI201500140A (es) Compuestos y composiciones terapéuticos
ECSP15026557A (es) Compuestos y sus métodos de empleo
ZA202208792B (en) Methods of treating and preventing graft versus host disease
GT201500249A (es) Terapia de combinación
CO7350624A2 (es) Inhibidores de la tirosina-quinasa de bruton
MX2021013837A (es) Enfoque de inmunoterapias de combinacion para el tratamiento del cancer.
CR20140108A (es) Compuesto de ciclopropanoamina
GT201300320A (es) Terapia de combinación que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cáncer.
UY35916A (es) Compuestos tricíclicos como agentes antineoplásicos inhibidores del bromodominio
CL2015002641A1 (es) Método para el tratamiento de la enfermedad de parkinson.
NI201400109A (es) Tratamiento del cáncer con inhibidores tor cinasa
PH12016502291A1 (en) Indolizine derivatives as phosphoinositide 3-kinases inhibitors
NI201400111A (es) Tratamiento del cáncer con inhibidores tor cinasa
CL2015002571A1 (es) Composiciones y métodos para le diagnostico y tratamiento del cáncer hepático.
SG10201808746QA (en) Methods for enhancing the efficacy of a tumor-directed immune response
CR20150211A (es) Compuestos diméricos
MX2019012938A (es) Uso del inhibidor mejorador de homologo zeste 2 (ezh2) combinado con el inhibidor tirosina cinasa de bruton (btk) en la preparacion de farmacos para tratar tumores.
CO7151543A2 (es) Combinaciones terapéuticas y métodos para tratar el melanoma
MX2015009277A (es) Formas de dosificacion y usos terapauticos de l-4-cloro quinurenina.
HN2009003001A (es) Uso de compuestos inhibidodres de quinaxolina de pi3k-alfa para el tratamiento del cancer
BR112017008659A2 (pt) ?métodos e compostos de agonista de gip?
UY34069A (es) Semuloparina para la prevención de tromboembolismo venoso en pacientes con cáncer que están recibiendo quimioterapia